GLASSIA Drug Insight

“GLASSIA Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about GLASSIA for Alpha-1 Antitrypsin Deficiency (AATD) in the US. A detailed picture of the GLASSIA for AATD in the United States for the study period 2019 –2032 is provided in this report along with a detailed description of the GLASSIA for AATD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the GLASSIA market forecast analysis for AATD in the United States, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in AATD.

Drug Summary

GLASSIA, is an A1-PI (human), indicated for chronic augmentation and maintenance therapy in individuals with clinically evident emphysema due to severe hereditary deficiency of A1 -PI, also known as AATD. GLASSIA increases antigenic and functional (anti-neutrophil elastase capacity, ANEC) serum levels and antigenic lung epithelial fluid levels of A1 -PI.

In 2016, Kamada and Shire (now a part of Takeda) launched GLASSIA as a new FDA-approved self-infusion indication for AATD. It is the first and only AATD treatment with this indication.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the GLASSIA description, mechanism of action, dosage and administration, research and development activities in AATD.
• Elaborated details on GLASSIA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the GLASSIA research and development activities in AATD across the United States.
• The report also covers the patents information with expiry timeline around GLASSIA.
• The report contains forecasted sales of GLASSIA for AATD till 2032.
• Comprehensive coverage of the late-stage emerging therapies for AATD.
• The report also features the SWOT analysis with analyst views for GLASSIA in AATD.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

GLASSIA Analytical Perspective by DelveInsight

In-depth GLASSIA Market Assessment

This report provides a detailed market assessment of GLASSIA for AATD in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.

GLASSIA Clinical Assessment

The report provides the clinical trials information of GLASSIA for AATD covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for AATD is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence GLASSIA dominance.
• Other emerging products for AATD are expected to give tough market competition to GLASSIA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of GLASSIA in AATD.
• Our in-depth analysis of the forecasted sales data of GLASSIA from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the GLASSIA in AATD.

Key Questions

• What is the product type, route of administration and mechanism of action of GLASSIA?
• What is the clinical trial status of the study related to GLASSIA in AATD and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the GLASSIA development?
• What are the key designations that have been granted to GLASSIA for AATD?
• What is the forecasted market scenario of GLASSIA for AATD?
• What are the forecasted sales of GLASSIA in the United States? 
• What are the other emerging products available and how are these giving competition to GLASSIA for AATD?
• Which are the late-stage emerging therapies under development for the treatment of AATD?